Trial Profile

Comparison of the effects of Belatacept and Anticalcineurins on endothelial function in kidney transplant patients - BELAFENDO - 2021/0391/HP

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Ciclosporin; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms BELAFENDO

Most Recent Events

15 Sep 2025 Planned End Date changed to 1 Aug 2027.
15 Sep 2025 Planned initiation date changed to 1 Oct 2025.
15 Sep 2025 Status changed from not stated to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com